Ocean Biomedical, Inc.
FRC CoverageOcean Biomedical, Inc.
FRC CoverageYour view on OCEA
Overview
What the company does, where it operates, and who runs it.
*Ocean Biomedical, Inc. has paid FRC a fee for research coverage and distribution of reports.
About Ocean Biomedical, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chirinjeev Kathuria
- Headquarters
- Room 325, 55 Claverick Street, Providence, RI, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chirinjeev Kathuria
- Headquarters
- Room 325, 55 Claverick Street, Providence, RI, US
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation.
The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients.
The company was incorporated in 2019 and is based in Providence, Rhode Island.
Research Reports
FRC analyst coverage and recommendations.
Past Reports
Historical coverage archive.
Analyst Notes
Ongoing commentary and updates from FRC analysts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Ocean Biomedical, Inc., and the rating behind it. OCEA last traded at $0.0020; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Ocean Biomedical, Inc.. Starting points for Ocean Biomedical, Inc.: EPS -$0.12, beta 1.43 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Ocean Biomedical, Inc.. Ocean Biomedical, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Ocean Biomedical, Inc.. Trailing twelve-month EPS for Ocean Biomedical, Inc. stands at -$0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Ocean Biomedical, Inc.. Ocean Biomedical, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Ocean Biomedical, Inc. valued side by side against its closest peers. Ocean Biomedical, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Ocean Biomedical, Inc., and how their positions are changing. At a $1.2M market value, institutional positions materially move Ocean Biomedical, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Ocean Biomedical, Inc. executives and directors. Shares of Ocean Biomedical, Inc. have traded between $0.0005 and $0.76 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Ocean Biomedical, Inc.. Ocean Biomedical, Inc. is a $1.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Ocean Biomedical, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Ocean Biomedical, Inc.. Coverage tracks Ocean Biomedical, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.